Home › Companies › STANDARD BIOTOOLS INC. › 2023-2024

STANDARD BIOTOOLS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and STANDARD BIOTOOLS INC.’s Form 8-K, filed 2024-07-01 (Item 5.07 on EDGAR). Page generated 02 October 2026.

18Reported items
143Asset managers
651Fund votes
2024-06-27Main meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore STANDARD BIOTOOLS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by STANDARD BIOTOOLS INC.

These tallies are STANDARD BIOTOOLS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-07-01 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. STANDARD BIOTOOLS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

STANDARD BIOTOOLS INC. — official shareholder meeting results, meeting held 2024-06-27 (Form 8-K, filed 2024-07-01)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Troy Cox	222,829,923	--	--	7,618,480	62,511,542	Majority: yes
Elect Director: Fenel M. Eloi	221,580,993	--	--	8,868,410	62,510,542	Majority: yes
Proposal 2: Advisory Vote on Approval of Executive Compensation.	200,835,452	28,960,018	653,932	--	62,510,543	Majority: yes
Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm.	291,606,384	383,526	970,035	--	--	Majority: yes
Proposal 4: Approval of the Amendment to the Amended and Restated 2011 Equity Incentive Plan.	219,832,074	10,192,031	425,296	--	62,510,544	Majority: yes

Source: STANDARD BIOTOOLS INC., Form 8-K, filed with the SEC on 2024-07-01 — read the filing on EDGAR.

STANDARD BIOTOOLS INC. — official shareholder meeting results, meeting held 2024-01-04 (Form 8-K, filed 2024-01-05)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 2. To approve the Charter Amendment (the "Standard BioTools Charter Amendment Proposal").	125,698,245	5,230,711	124,663	--	--	Majority: yes
Proposal 4. To approve the A&R 2011 Plan Amendment.	119,362,194	11,536,749	154,676	--	--	Majority: yes

Source: STANDARD BIOTOOLS INC., Form 8-K, filed with the SEC on 2024-01-05 — read the filing on EDGAR.

How asset managers voted at the STANDARD BIOTOOLS INC. 2023-2024 meetings

Each item below shows how the 143 asset managers that disclosed a STANDARD BIOTOOLS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of STANDARD BIOTOOLS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-06-27.

Combines 8 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 200,835,452AGAINST: 28,960,018

STANDARD BIOTOOLS INC.’s own tally for this item (“Proposal 2: Advisory Vote on Approval of Executive Compensation.”): 200,835,452 for, 28,960,018 against, per its Form 8-K filed 2024-07-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 124 asset managers below cast 84% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 84%AGAINST 16%

FOR: 84.2%AGAINST: 15.8%ABSTAIN: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy ” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Against	Vote
VIKING GLOBAL INVESTORS LP	58,651,170	0	For
Morgan Stanley	14,814,020	0	For
Vanguard	13,241,876	0	For
ARK ETF Trust	13,046,212	0	For
Nikko Asset Management Americas, Inc.	0	9,349,418	Against
BlackRock	14,370	5,153,055	Against
Neuberger Berman	4,937,862	0	For
PRIMECAP MANAGEMENT CO/CA/	3,008,643	0	For
Indaba Capital Management, L.P.	0	2,879,857	Against
PRIMECAP Odyssey Funds	2,153,269	0	For
BALYASNY ASSET MANAGEMENT L.P.	2,032,290	0	For
Equitable	1,739,957	46,242	For
Nikko Asset Management Co., Ltd.	0	1,677,117	Against
Slate Path Capital LP	1,563,477	0	For
Tikvah Management LLC	1,461,947	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,439,488	0	For
Fidelity	1,180,239	104,377	For
State Street	1,098,638	82,899	For
Invenomic Capital Management LP	985,564	0	For
NEEDHAM FUNDS INC	950,000	0	For
Northern Trust	806,845	8,331	For
NORTHERN LIGHTS FUND TRUST II	541,597	0	For
STRS OHIO	0	454,169	Against
Redmile Group, LLC	411,631	0	For
Renaissance	0	400,421	Against

Showing the 25 largest of 124 asset managers. See all 124 in the interactive database.

2. Standard BioTools Advisory Compensation Proposal. To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools' named executive officers and to SomaLogic's Chief Executive Officer that is based on or otherwise relates to the Merger, as disclosed in "The Merger - Interests of Standard BioTools Directors and Executive Officers in the Merger - Quantifica

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-01-04.

Combines 2 wordings of this item as funds reported it.

87% fund support · no official result

FOR 87%13%

The 44 asset managers below cast 87% of the shares they voted on this item FOR (20,068,696 for, 3,059,943 against).

FOR: 20,068,696 (86.8%)AGAINST: 3,059,943 (13.2%)

Largest asset managers voting on “Standard BioTools Advisory Compensation Proposal. To approve, on a non-binding, advisory basis, the compensati” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Against	Vote
Morgan Stanley	5,092,734	0	For
Neuberger Berman	4,858,101	0	For
Vanguard	4,095,001	0	For
PRIMECAP MANAGEMENT CO/CA/	0	3,059,943	Against
BlackRock	1,245,854	0	For
BALYASNY ASSET MANAGEMENT L.P.	731,756	0	For
GEODE CAPITAL MANAGEMENT, LLC	609,345	0	For
Equitable	597,551	0	For
Fidelity	538,416	0	For
STRS OHIO	483,940	0	For
State Street	279,537	0	For
Renaissance	272,060	0	For
BRIDGEWAY FUNDS INC	212,000	0	For
HighTower Advisors, LLC	188,700	0	For
BNY Mellon	158,724	0	For
VIKING GLOBAL INVESTORS LP	127,779	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	92,493	0	For
MELLON INVESTMENTS Corp	86,105	0	For
Charles Schwab	62,384	0	For
Polar Capital Holdings Plc	56,585	0	For
RBC Dominion Securities Inc.	50,235	0	For
SEI	49,616	0	For
T. Rowe Price	38,400	0	For
Citadel	36,894	0	For
Dimensional	20,355	0	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

3. To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools Inc. named executive officers and to SomaLogic, Inc.'s Chief Executive Officer that is based on or otherwise relates to the merger.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-01-04.

Combines 2 wordings of this item as funds reported it.

81% fund support · no official result

FOR 81%AGAINST 19%

The 32 asset managers below cast 81% of the shares they voted on this item FOR (9,852,489 for, 2,320,639 against).

FOR: 9,852,489 (80.9%)AGAINST: 2,320,639 (19.1%)ABSTAIN: 264 (0.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools In” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Indaba Capital Management, L.P.	7,446,229	0	0	For
PRIMECAP Odyssey Funds	0	2,195,369	0	Against
NEEDHAM FUNDS INC	1,190,000	0	0	For
BOOTHBAY FUND MANAGEMENT, LLC	774,014	0	0	For
NEXPOINT FUNDS I	154,262	0	0	For
ROCKEFELLER FINANCIAL LLC	152,208	0	0	For
SILVERBACK ASSET MANAGEMENT LLC	0	125,000	0	Against
NEEDHAM INVESTMENT MANAGEMENT LLC	34,435	0	0	For
Main Management LLC	23,000	0	0	For
Northern Trust	22,031	0	0	For
FIRST WILSHIRE SECURITIES MANAGEMENT INC	19,085	0	0	For
MEYER HANDELMAN CO	17,500	0	0	For
ENVESTNET ASSET MANAGEMENT INC	5,872	0	0	For
LPL Financial LLC	2,248	0	0	For
MERCER GLOBAL ADVISORS INC /ADV	2,001	0	0	For
Belpointe Asset Management LLC	2,000	0	0	For
PNC BANK, NATIONAL ASSOCIATION	1,932	0	0	For
John Hancock	1,624	0	0	For
LEVIN CAPITAL STRATEGIES, L.P.	1,570	0	0	For
Corient Private Wealth LLC	1,320	0	0	For
Security National Bank	565	0	0	For
Mirador Capital Partners LP	0	0	264	Abstain
BCS Wealth Management	200	0	0	For
PINNACLE ASSOCIATES LTD	0	200	0	Against
UNITED CAPITAL FINANCIAL ADVISORS, LLC	127	0	0	For

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

4. To vote to elect two (2) nominees as Class II Directors, each to a term expiring at our 2027 annual meeting of stockholders and to hold office until his successor is duly elected and qualified: Troy Cox

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-06-27.

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 222,829,923WITHHELD: 7,618,480

STANDARD BIOTOOLS INC.’s own tally for this item (“Elect Director: Troy Cox”): 222,829,923 for, 7,618,480 withheld, per its Form 8-K filed 2024-07-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 25 asset managers below cast 100% of the shares they voted on this item FOR (39,618,945 for, 0 against).

FOR 99.8%

FOR: 39,618,945 (99.8%)ABSTAIN: 72,060 (0.2%)

Largest asset managers voting on “To vote to elect two (2) nominees as Class II Directors, each to a term expiring at our 2027 annual meeting of” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Abstain	Vote
ARK ETF Trust	13,046,212	0	For
Vanguard	12,987,923	0	For
Morgan Stanley	3,735,804	0	For
PRIMECAP Odyssey Funds	2,153,269	0	For
Equitable	1,786,199	0	For
Fidelity	1,280,779	0	For
Neuberger Berman	1,176,340	0	For
NEEDHAM FUNDS INC	950,000	0	For
BlackRock	866,875	0	For
NORTHERN LIGHTS FUND TRUST II	541,597	0	For
PARADIGM FUNDS	301,600	0	For
TRUST FOR PROFESSIONAL MANAGERS	260,783	0	For
BRIDGEWAY FUNDS INC	177,000	0	For
Northern Trust	119,504	0	For
Charles Schwab	111,584	0	For
Dimensional	0	72,060	Abstain
Victory Capital	36,686	0	For
American Century	26,410	0	For
BNY Mellon	23,182	0	For
Invesco	18,127	0	For
State Street	10,677	0	For
John Hancock	6,488	0	For
Nationwide	1,451	0	For
Guggenheim	454	0	For
New York Life	1	0	For

5. To vote to elect two (2) nominees as Class II Directors, each to a term expiring at our 2027 annual meeting of stockholders and to hold office until his successor is duly elected and qualified: Fenel M. Eloi

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-06-27.

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 221,580,993WITHHELD: 8,868,410

STANDARD BIOTOOLS INC.’s own tally for this item (“Elect Director: Fenel M. Eloi”): 221,580,993 for, 8,868,410 withheld, per its Form 8-K filed 2024-07-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 25 asset managers below cast 100% of the shares they voted on this item FOR (39,322,441 for, 0 against).

FOR 99.0%

FOR: 39,322,441 (99.1%)ABSTAIN: 368,564 (0.9%)

Largest asset managers voting on “To vote to elect two (2) nominees as Class II Directors, each to a term expiring at our 2027 annual meeting of” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Abstain	Vote
ARK ETF Trust	13,046,212	0	For
Vanguard	12,987,923	0	For
Morgan Stanley	3,735,804	0	For
PRIMECAP Odyssey Funds	2,153,269	0	For
Equitable	1,786,199	0	For
Fidelity	1,280,779	0	For
Neuberger Berman	1,176,340	0	For
NEEDHAM FUNDS INC	950,000	0	For
BlackRock	866,875	0	For
NORTHERN LIGHTS FUND TRUST II	541,597	0	For
PARADIGM FUNDS	301,600	0	For
TRUST FOR PROFESSIONAL MANAGERS	260,783	0	For
BRIDGEWAY FUNDS INC	0	177,000	Abstain
Northern Trust	0	119,504	Abstain
Charles Schwab	111,584	0	For
Dimensional	0	72,060	Abstain
Victory Capital	36,686	0	For
American Century	26,410	0	For
BNY Mellon	23,182	0	For
Invesco	18,127	0	For
State Street	10,677	0	For
John Hancock	6,488	0	For
Nationwide	1,451	0	For
Guggenheim	454	0	For
New York Life	1	0	For

6. To approve an amendment to our Amended and Restated 2011 Equity Incentive Plan, as amended, to increase the number of shares of common stock available for issuance thereunder by 19,125,000 shares.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2024-06-27.

96% Majority: yes · of votes cast

FOR 96%

FOR: 219,832,074AGAINST: 10,192,031

STANDARD BIOTOOLS INC.’s own tally for this item (“Proposal 4: Approval of the Amendment to the Amended and Restated 2011 Equity Incentive Plan.”): 219,832,074 for, 10,192,031 against, per its Form 8-K filed 2024-07-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 23 asset managers below cast 99.5% of the shares they voted on this item FOR (38,282,814 for, 156,591 against).

FOR 99.5%

FOR: 38,282,814 (99.6%)AGAINST: 156,591 (0.4%)

Largest asset managers voting on “To approve an amendment to our Amended and Restated 2011 Equity Incentive Plan, as amended, to increase the nu” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Against	Vote
ARK ETF Trust	13,046,212	0	For
Vanguard	12,987,923	0	For
Morgan Stanley	3,735,804	0	For
PRIMECAP Odyssey Funds	2,153,269	0	For
Equitable	1,786,199	0	For
Fidelity	1,280,779	0	For
Neuberger Berman	1,176,340	0	For
BlackRock	866,875	0	For
NORTHERN LIGHTS FUND TRUST II	541,597	0	For
TRUST FOR PROFESSIONAL MANAGERS	260,783	0	For
BRIDGEWAY FUNDS INC	177,000	0	For
Northern Trust	0	119,504	Against
Charles Schwab	111,584	0	For
Dimensional	72,060	0	For
Victory Capital	36,686	0	For
American Century	0	26,410	Against
BNY Mellon	23,182	0	For
Invesco	18,127	0	For
State Street	0	10,677	Against
John Hancock	6,488	0	For
Nationwide	1,451	0	For
Guggenheim	454	0	For
New York Life	1	0	For

7. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2024-06-27.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 291,606,384AGAINST: 383,526

STANDARD BIOTOOLS INC.’s own tally for this item (“Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm.”): 291,606,384 for, 383,526 against, per its Form 8-K filed 2024-07-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 23 asset managers below cast 100% of the shares they voted on this item FOR (38,439,405 for, 0 against).

FOR 100%

FOR: 38,439,405 (100.0%)

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm f” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Vote
ARK ETF Trust	13,046,212	For
Vanguard	12,987,923	For
Morgan Stanley	3,735,804	For
PRIMECAP Odyssey Funds	2,153,269	For
Equitable	1,786,199	For
Fidelity	1,280,779	For
Neuberger Berman	1,176,340	For
BlackRock	866,875	For
NORTHERN LIGHTS FUND TRUST II	541,597	For
TRUST FOR PROFESSIONAL MANAGERS	260,783	For
BRIDGEWAY FUNDS INC	177,000	For
Northern Trust	119,504	For
Charles Schwab	111,584	For
Dimensional	72,060	For
Victory Capital	36,686	For
American Century	26,410	For
BNY Mellon	23,182	For
Invesco	18,127	For
State Street	10,677	For
John Hancock	6,488	For
Nationwide	1,451	For
Guggenheim	454	For
New York Life	1	For

8. Standard BioTools 2011 Equity Incentive Plan Amendment Proposal. To approve an amendment to the Standard BioTools Amended and Restated 2011 Equity Incentive Plan, as amended (the "A&R 2011 Plan"), to increase the aggregate number of shares of Standard BioTools Common Stock that are available for issuance thereunder by 15,000,000 shares (the "Standard BioTools Equity Incentive Plan Amendment Propos

COMPENSATIONMajority of the votes cast: yes

Meeting held 2024-01-04.

Combines 4 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 119,362,194AGAINST: 11,536,749

STANDARD BIOTOOLS INC.’s own tally for this item (“Proposal 4. To approve the A&R 2011 Plan Amendment.”): 119,362,194 for, 11,536,749 against, per its Form 8-K filed 2024-01-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 20 asset managers below cast 82% of the shares they voted on this item FOR (9,779,746 for, 2,212,333 against).

FOR 82%AGAINST 18%

FOR: 9,779,746 (81.6%)AGAINST: 2,212,333 (18.4%)

Largest asset managers voting on “Standard BioTools 2011 Equity Incentive Plan Amendment Proposal. To approve an amendment to the Standard BioTo” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	4,068,266	0	For
PRIMECAP Odyssey Funds	0	2,195,369	Against
Neuberger Berman	1,468,160	0	For
Morgan Stanley	1,295,362	0	For
NEEDHAM FUNDS INC	1,190,000	0	For
Equitable	597,551	0	For
Fidelity	538,365	0	For
BRIDGEWAY FUNDS INC	212,000	0	For
NEXPOINT FUNDS I	154,262	0	For
BlackRock	76,562	0	For
ALGERT GLOBAL LLC	61,560	0	For
BNY Mellon	52,908	0	For
Charles Schwab	31,192	0	For
Dimensional	20,355	0	For
Northern Trust	0	16,964	Against
Victory Capital	8,484	0	For
Nationwide	2,446	0	For
John Hancock	1,624	0	For
Guggenheim	454	0	For
Series Portfolios Trust	195	0	For

9. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-06-05; no official results are on file for this meeting.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 16 asset managers below cast 100% of the shares they voted on this item FOR (996,767 for, 0 against).

FOR: 996,767 (100.0%)ABSTAIN: 67 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy ” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Abstain	Vote
NEEDHAM FUNDS INC	950,000	0	For
NEEDHAM INVESTMENT MANAGEMENT LLC	34,435	0	For
BBR PARTNERS, LLC	7,886	0	For
BlackRock	3,568	0	For
Bleakley Financial Group, LLC	438	0	For
BCS Wealth Management	200	0	For
PINNACLE ASSOCIATES LTD	200	0	For
Mirador Capital Partners LP	0	67	Abstain
Capital Group	40	0	For
ADVISOR PARTNERS II, LLC	0	0	--
ENVESTNET ASSET MANAGEMENT INC	0	0	--
Goldman Sachs	0	0	--
LPL Financial LLC	0	0	--
LUMINUS MANAGEMENT LLC	0	0	--
MERCER GLOBAL ADVISORS INC /ADV	0	0	--
SILVERBACK ASSET MANAGEMENT LLC	0	0	--

10. Standard BioTools Adjournment Proposal. To approve adjournments of the Standard BioTools Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Standard BioTools Share Issuance Proposal and the Standard BioTools Charter Amendment Proposal if there are insufficient votes at the time of such adjournment to approve such proposals or to ensure tha

CORPORATE GOVERNANCE

Meeting held 2024-01-04.

Combines 2 wordings of this item as funds reported it.

94% fund support · no official result

FOR 94%

The 15 asset managers below cast 94% of the shares they voted on this item FOR (7,850,899 for, 538,365 against).

FOR: 7,850,899 (93.6%)AGAINST: 538,365 (6.4%)

Largest asset managers voting on “Standard BioTools Adjournment Proposal. To approve adjournments of the Standard BioTools Special Meeting from ” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	4,068,266	0	For
Neuberger Berman	1,468,160	0	For
Morgan Stanley	1,295,362	0	For
Equitable	597,551	0	For
Fidelity	0	538,365	Against
BRIDGEWAY FUNDS INC	212,000	0	For
BlackRock	76,562	0	For
BNY Mellon	52,908	0	For
Charles Schwab	31,192	0	For
Dimensional	20,355	0	For
Northern Trust	16,964	0	For
Victory Capital	8,484	0	For
Nationwide	2,446	0	For
Guggenheim	454	0	For
Series Portfolios Trust	195	0	For

11. Standard BioTools Charter Amendment Proposal. To approve an amendment to the Standard BioTools Eighth Amended and Restated Certificate of Incorporation, as amended (the "Standard BioTools Charter"), to increase the total number of shares of Standard BioTools Common Stock authorized for issuance thereunder from 400,000,000 shares to 600,000,000 shares (the "Standard BioTools Charter Amendment Propo

CAPITAL STRUCTURE

Meeting held 2024-01-04.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 15 asset managers below cast 100% of the shares they voted on this item FOR (8,389,264 for, 0 against).

FOR: 8,389,264 (100.0%)

Largest asset managers voting on “Standard BioTools Charter Amendment Proposal. To approve an amendment to the Standard BioTools Eighth Amended ” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Vote
Vanguard	4,068,266	For
Neuberger Berman	1,468,160	For
Morgan Stanley	1,295,362	For
Equitable	597,551	For
Fidelity	538,365	For
BRIDGEWAY FUNDS INC	212,000	For
BlackRock	76,562	For
BNY Mellon	52,908	For
Charles Schwab	31,192	For
Dimensional	20,355	For
Northern Trust	16,964	For
Victory Capital	8,484	For
Nationwide	2,446	For
Guggenheim	454	For
Series Portfolios Trust	195	For

12. Standard BioTools Share Issuance Proposal. To approve the issuance of shares of common stock, par value $0.001 per share, of Standard BioTools ("Standard BioTools Common Stock") in connection with the Merger and in accordance with Nasdaq Listing Rule 5635(a) (the "Standard BioTools Share Issuance Proposal");

EXTRAORDINARY TRANSACTIONS

Meeting held 2024-01-04.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 15 asset managers below cast 100% of the shares they voted on this item FOR (8,389,264 for, 0 against).

FOR: 8,389,264 (100.0%)

Largest asset managers voting on “Standard BioTools Share Issuance Proposal. To approve the issuance of shares of common stock, par value $0.001” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Vote
Vanguard	4,068,266	For
Neuberger Berman	1,468,160	For
Morgan Stanley	1,295,362	For
Equitable	597,551	For
Fidelity	538,365	For
BRIDGEWAY FUNDS INC	212,000	For
BlackRock	76,562	For
BNY Mellon	52,908	For
Charles Schwab	31,192	For
Dimensional	20,355	For
Northern Trust	16,964	For
Victory Capital	8,484	For
Nationwide	2,446	For
Guggenheim	454	For
Series Portfolios Trust	195	For

13. To approve adjournments of the Standard BioTools Inc. Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Standard BioTools Share Issuance Proposal and the Standard BioTools Charter Amendment Proposal if there are insufficient votes at the time of such adjournment to approve such proposals.

CORPORATE GOVERNANCE

Meeting held 2024-01-04.

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (3,541,255 for, 0 against).

FOR: 3,541,255 (100.0%)

Largest asset managers voting on “To approve adjournments of the Standard BioTools Inc. Special Meeting from time to time, if necessary or appro” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Vote
PRIMECAP Odyssey Funds	2,195,369	For
NEEDHAM FUNDS INC	1,190,000	For
NEXPOINT FUNDS I	154,262	For
John Hancock	1,624	For

14. To approve an amendment to the Standard BioTools Eighth Amended and Restated Certificate of Incorporation, as amended, to increase the total number of shares of Standard BioTools Inc. common stock, par value $0.001 per share, authorized for issuance thereunder from 400,000,000 shares to 600,000,000 shares (the "Standard BioTools Charter Amendment Proposal").

CAPITAL STRUCTURE

Meeting held 2024-01-04.

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (3,541,255 for, 0 against).

FOR: 3,541,255 (100.0%)

Largest asset managers voting on “To approve an amendment to the Standard BioTools Eighth Amended and Restated Certificate of Incorporation, as ” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Vote
PRIMECAP Odyssey Funds	2,195,369	For
NEEDHAM FUNDS INC	1,190,000	For
NEXPOINT FUNDS I	154,262	For
John Hancock	1,624	For

15. To approve the issuance of shares of common stock, par value $0.001 per share, of Standard BioTools Inc. in connection with the merger and in accordance with Nasdaq Listing Rule 5635(a) (the "Standard BioTools Share Issuance Proposal").

EXTRAORDINARY TRANSACTIONSCAPITAL STRUCTURE

Meeting held 2024-01-04.

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (3,541,255 for, 0 against).

FOR: 3,541,255 (100.0%)

Largest asset managers voting on “To approve the issuance of shares of common stock, par value $0.001 per share, of Standard BioTools Inc. in co” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Vote
PRIMECAP Odyssey Funds	2,195,369	For
NEEDHAM FUNDS INC	1,190,000	For
NEXPOINT FUNDS I	154,262	For
John Hancock	1,624	For

16. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-01-04.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (225,792 for, 0 against).

FOR: 225,792 (100.0%)

Largest asset managers voting on “14A Executive Compensation” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
DIKER MANAGEMENT LLC	224,824	0	0	0	For
Granite Investment Partners, LLC	968	0	0	0	For

17. Advisory Vote on Golden Parachutes

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-01-04.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (111,560 for, 0 against).

FOR: 111,560 (100.0%)

Largest asset managers voting on “Advisory Vote on Golden Parachutes” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
ALGERT GLOBAL LLC	61,560	0	0	0	For
PARADIGM CAPITAL MANAGEMENT INC/NY	50,000	0	0	0	For

18. To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools' named executive officers and to SomaLogic's Chief Executive Officer that is based on or otherwise relates to the Merger, as disclosed in "The Merger - Interests of Standard BioTools Directors and Executive Officers in teh Merger - Quantification of Potential Payments to Standard BioTools Na

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-01-04.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (7,856 for, 0 against).

FOR: 7,856 (100.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools' n” at STANDARD BIOTOOLS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
Orion Porfolio Solutions, LLC	3,928	0	0	0	For
Orion Portfolio Solutions, LLC	3,928	0	0	0	For

Largest STANDARD BIOTOOLS INC. shareholders voting in 2023-2024

Ranked by the number of STANDARD BIOTOOLS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 79,395,035 shares outstanding at the time of that meeting.

Top STANDARD BIOTOOLS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	VIKING GLOBAL INVESTORS LP	73.87%
2	Morgan Stanley	18.66%
3	Vanguard	16.68%
4	ARK ETF Trust	16.43%
5	Nikko Asset Management Americas, Inc.	11.78%
6	BlackRock	6.51%
7	Neuberger Berman	6.22%
8	PRIMECAP MANAGEMENT CO/CA/	3.79%
9	Indaba Capital Management, L.P.	3.63%
10	PRIMECAP Odyssey Funds	2.71%

Reported STANDARD BIOTOOLS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

STANDARD BIOTOOLS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
S	86.91%	13D
BlackRock	31.39%	13F
Vanguard Group	21.72%	13F
Millennium Management	18.10%	13F
Morgan Stanley	8.00%	13F
Geode Capital	3.41%	13F
State Street	1.69%	13F
Goldman Sachs	1.63%	13F
Dimensional Fund Advisors	1.60%	13F
Renaissance Technologies	1.58%	13F

Percentages above are of 79,395,035 shares outstanding, as reported by STANDARD BIOTOOLS INC. on its Form 10-Q dated 2023-11-03 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from STANDARD BIOTOOLS INC.’s 10-Q dated 2023-11-03. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At STANDARD BIOTOOLS INC.'s 3 shareholder meetings in the 2023-2024 proxy season (held 2024-01-04, 2024-06-05 and 2024-06-27), 143 asset managers reported how they voted in their SEC Form N-PX filings, covering 651 separate fund positions. Their filings are grouped here into 18 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held 2024-06-27 — To approve, on an advisory basis, the compensation of our named executive officers as disclosed… — FOR was 87% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: STANDARD BIOTOOLS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-07-01.

STANDARD BIOTOOLS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.